Compare MYSZ & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | VBIO |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 1.1M |
| IPO Year | 2017 | 2021 |
| Metric | MYSZ | VBIO |
|---|---|---|
| Price | $1.05 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 65.8K | ★ 658.1K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $142,000.00 | ★ $780,000.00 |
| Revenue This Year | $38.86 | N/A |
| Revenue Next Year | $9.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.37 | $0.12 |
| 52 Week High | $298.80 | $812.50 |
| Indicator | MYSZ | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 23.25 | 22.28 |
| Support Level | $0.37 | $0.12 |
| Resistance Level | $2.60 | $4.39 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.27 | 1.97 |
| Stochastic Oscillator | 6.45 | 0.75 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.